Cargando…

Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer

PURPOSE: Multiple treatment options exist for patients with metastatic breast cancer (MBC). However, limited information is available on the impact of prior treatment duration and class on survival outcome for novel therapies, such as cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franks, Jeffrey, Caston, Nicole E., Elkhanany, Ahmed, Gerke, Travis, Azuero, Andres, Rocque, Gabrielle B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883320/ https://www.ncbi.nlm.nih.gov/pubmed/36539670 http://dx.doi.org/10.1007/s10549-022-06823-w

Ejemplares similares

Prior Treatment Time Affects Survival Outcomes in Metastatic Breast Cancer
por: Rocque, Gabrielle B., et al.
Publicado: (2020)

Examining the association among fear of COVID‐19, psychological distress, and delays in cancer care
por: Caston, Nicole E., et al.
Publicado: (2021)

Long‐term survival of nonlocalized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis: The extreme study
por: Baandrup, Louise, et al.
Publicado: (2022)

Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre
por: Daniel, C R, et al.
Publicado: (2016)

Role of hormonal risk factors in HER2-positive breast carcinomas
por: Balsari, A, et al.
Publicado: (2003)

Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases
por: Shafrir, Amy L, et al.
Publicado: (2016)

Racial and Ethnic Variation in Health-Related Quality of Life Scores Prior to Prostate Cancer Treatment
por: Reading, Stephanie R., et al.
Publicado: (2017)

Evaluating the implementation and impact of navigator-supported remote symptom monitoring and management: a protocol for a hybrid type 2 clinical trial
por: Rocque, Gabrielle B., et al.
Publicado: (2022)

Socioeconomic position, treatment, and survival of non-Hodgkin lymphoma in Denmark – a nationwide study
por: Frederiksen, B L, et al.
Publicado: (2012)

Prediagnostic circulating levels of sex hormones and survival in esophageal adenocarcinoma
por: Xie, Shao‐Hua, et al.
Publicado: (2020)

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors
por: Truin, Wilfred, et al.
Publicado: (2017)

Pathogenesis and progression of oesophageal adenocarcinoma varies by prior diagnosis of Barrett's oesophagus
por: Cook, Michael B, et al.
Publicado: (2016)

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands
por: van Dooijeweert, Carmen, et al.
Publicado: (2019)

The Relationship Between Prior Cancer Diagnosis and All-Cause Dementia Progression Among U.S. Adults
por: Fowler, Mackenzie, et al.
Publicado: (2021)

The hormonal profile of benign breast disease
por: Samoli, E, et al.
Publicado: (2013)

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer
por: Zhou, Jinmei, et al.
Publicado: (2022)

A rapid assessment of post-disclosure experiences of urban HIV-positive and HIV-negative school-aged children in Kenya
por: Gachanja, Grace
Publicado: (2015)

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival
por: Vos, Elvira L., et al.
Publicado: (2017)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

Cancer-Related Financial Hardship Screening as Part of Practice Transformation
por: Williams, Courtney P., et al.
Publicado: (2023)

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2021)

Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation
por: Abubakar, Mustapha, et al.
Publicado: (2018)

Antibiotic prescribing on admission to patients with pneumonia and prior outpatient antibiotic treatment: a cohort study on clinical outcome
por: van de Garde, Ewoudt M W, et al.
Publicado: (2015)

'Socioeconomic position and survival after cervical cancer: influence of cancer stage, comorbidity and smoking among Danish women diagnosed between 2005 and 2010
por: Ibfelt, E H, et al.
Publicado: (2013)

Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas
por: Lindblad, M, et al.
Publicado: (2006)

Pharmaceutically treated anxiety but not depression prior to cancer diagnosis predicts the onset of cardiovascular disease among breast cancer survivors
por: Schoormans, Dounya, et al.
Publicado: (2017)

A case–control study of endogenous hormones and cervical cancer
por: Shields, T S, et al.
Publicado: (2004)

Hormone‐related diseases and prostate cancer: An English national record linkage study
por: Watts, Eleanor L., et al.
Publicado: (2019)

Evaluating Nurses' Time to Response by Severity and Cancer Stage in a Remote Symptom Monitoring Program for Patients With Breast Cancer
por: Caston, Nicole E., et al.
Publicado: (2023)

Persistence with opioids post discharge from hospitalisation for surgery in Australian adults: a retrospective cohort study
por: Roughead, Elizabeth Ellen, et al.
Publicado: (2019)

An overview of menopausal oestrogen–progestin hormone therapy and breast cancer risk
por: Lee, S A, et al.
Publicado: (2005)

A prospective study of postmenopausal hormone use and ovarian cancer risk
por: Danforth, K N, et al.
Publicado: (2007)

Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer
por: Onland-Moret, N C, et al.
Publicado: (2003)

Hormonal risk factors and invasive epithelial ovarian cancer risk by parity
por: Bodelon, C, et al.
Publicado: (2013)

Anti-Mullerian hormone and endometrial cancer: a multi-cohort study
por: Fortner, Renée T, et al.
Publicado: (2017)

Hormone Levels and Sexual Functioning After Risk-Reducing Salpingo-Oophorectomy
por: Johansen, Nora, et al.
Publicado: (2018)

Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database
por: Kawai, Masaaki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_adi8m3g20nu60488oqlc1s2k3n